{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127927","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.357564+00:00","generated_at":"2026-05-29T23:07:42.791420+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet opens ADI-270 Phase 1 enrollment in ccRCC, doses first lupus nephritis patient with ADI-001","bullets":["Enrollment opened for Phase 1 trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma; preliminary data expected 1H25.","First lupus nephritis patient dosed in Phase 1 trial of ADI-001; preliminary clinical data in LN anticipated 1H25.","ADI-001 received FDA Fast Track Designation for relapsed/refractory class III or IV lupus nephritis.","Company expects to begin enrollment in SLE, SSc, IIM, SPS in 1Q25 and AAV in 2H25.","ADI-270 is the first gamma delta CAR T cell therapy for solid tumors to enter clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127927","json":"https://secwatch.observer/filing/0000950170-24-127927.json","markdown":"https://secwatch.observer/filing/0000950170-24-127927.md","text":"https://secwatch.observer/filing/0000950170-24-127927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024127927/0000950170-24-127927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024127927/acet-20241118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:07:42.791420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}